Keilholz U, Eggermont A M
Department of Medicine III (Hematology, Oncology, and Transfusion Medicine), University Hospital Benjamin Franklin, Free University of Berlin, Germany.
Oncology. 2000 Feb;58(2):89-95. doi: 10.1159/000012085.
Cytokine-based treatment regimens have been evaluated for advanced melanoma in a number of phase I and phase II trials within the last decade. Treatment with interleukin-2 (IL-2) as a single agent has resulted in response rates of approximately 15%, if a high dose of IL-2 is administered. Combination of interferon-alpha (IFNalpha) and high dose IL-2 yields response rates ranging from 10 to 41%. Response rates exceeding 50% have been reported with chemoimmunotherapy, if the treatment regimens included at least the three agents IL-2, IFNalpha and cisplatin. Recent randomized trials have evaluated the impact of these drugs on the survival of patients with advanced melanoma. The current 'state of the art' is discussed in this review.
在过去十年中，多项I期和II期试验对基于细胞因子的治疗方案用于晚期黑色素瘤进行了评估。如果给予高剂量的白细胞介素-2（IL-2）作为单一药物治疗，有效率约为15%。α干扰素（IFNα）与高剂量IL-2联合使用时，有效率在10%至41%之间。如果化疗免疫治疗方案至少包括IL-2、IFNα和顺铂这三种药物，据报道有效率超过50%。近期的随机试验评估了这些药物对晚期黑色素瘤患者生存的影响。本综述讨论了当前的“最新技术水平”。
